These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11097340)

  • 21. Expression profiling of selected genes of toxication and detoxication pathways in peripheral blood lymphocytes as a biomarker for predicting toxicity of environmental chemicals.
    Sharma A; Saurabh K; Yadav S; Jain SK; Parmar D
    Int J Hyg Environ Health; 2013 Nov; 216(6):645-51. PubMed ID: 23273579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer pharmacogenomics: achievements in basic research.
    Nakajima M; Yokoi T
    Int J Clin Oncol; 2005 Feb; 10(1):14-9. PubMed ID: 15729595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Gene-swap knock-in" cassette in mice to study allelic differences in human genes.
    Nebert DW; Dalton TP; Stuart GW; Carvan MJ
    Ann N Y Acad Sci; 2000; 919():148-70. PubMed ID: 11083106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relevance of xenobiotic metabolism in the interindividual susceptibility to chemicals.
    Testai E
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():48-9. PubMed ID: 11820624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism.
    Banerjee BD; Kumar R; Thamineni KL; Shah H; Thakur GK; Sharma T
    Curr Drug Metab; 2019; 20(14):1103-1113. PubMed ID: 31933442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutrition, genetics, and risks of cancer.
    Rock CL; Lampe JW; Patterson RE
    Annu Rev Public Health; 2000; 21():47-64. PubMed ID: 10884945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms in drug-metabolizing enzymes and drug targets.
    Hiratsuka M; Mizugaki M
    Mol Genet Metab; 2001 Aug; 73(4):298-305. PubMed ID: 11509011
    [No Abstract]   [Full Text] [Related]  

  • 29. [Genetic polymorphisms in drug-metabolizing enzymes].
    Saruwatari J; Nakagawa K; Ishizaki T
    Nihon Rinsho; 2002 Jan; 60(1):58-63. PubMed ID: 11808340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
    Brandon EF; Bosch TM; Deenen MJ; Levink R; van der Wal E; van Meerveld JB; Bijl M; Beijnen JH; Schellens JH; Meijerman I
    Toxicol Appl Pharmacol; 2006 Feb; 211(1):1-10. PubMed ID: 15975613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes.
    Okey AB; Boutros PC; Harper PA
    Pharmacogenet Genomics; 2005 Jun; 15(6):371-9. PubMed ID: 15900209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically determined differences in drug metabolism as a risk factor in drug toxicity.
    Eichelbaum M; Kroemer HK; Mikus G
    Toxicol Lett; 1992 Dec; 64-65 Spec No():115-22. PubMed ID: 1471165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variability in susceptibility and response to toxicants.
    Ingelman-Sundberg M
    Toxicol Lett; 2001 Mar; 120(1-3):259-68. PubMed ID: 11323184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers in aquatic plants: selection and utility.
    Brain RA; Cedergreen N
    Rev Environ Contam Toxicol; 2009; 198():49-109. PubMed ID: 19253039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related disparities: influence of environmental factors.
    Olden K; White SL
    Med Clin North Am; 2005 Jul; 89(4):721-38. PubMed ID: 15925646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.
    Sim SC; Kacevska M; Ingelman-Sundberg M
    Pharmacogenomics J; 2013 Feb; 13(1):1-11. PubMed ID: 23089672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants.
    Yi B; Yang JY; Yang M
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(4):353-77. PubMed ID: 18000786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway.
    Skuladottir H; Autrup H; Autrup J; Tjoenneland A; Overvad K; Ryberg D; Haugen A; Olsen JH
    Lung Cancer; 2005 May; 48(2):187-99. PubMed ID: 15829318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics: detecting sensitive populations.
    Shields PG
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):81-7. PubMed ID: 7737047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.